ストックスクリーナーアプリを入手
9.39
4.57%
-0.46
前日終値:
$9.85
開ける：
$10.39
24時間の取引高:
350.15K
Relative Volume:
0.27
時価総額：
$620.12M
収益：
$2.81M
当期純損益:
$-97.34M
株価収益率:
-5.943
EPS:
-1.58
ネットキャッシュフロー:
$-91.47M
1週間 パフォーマンス:
-13.28%
1か月 パフォーマンス:
-27.69%
6か月 パフォーマンス:
+20.05%
1年 パフォーマンス:
+115.10%
1日の値動き範囲:
$9.36
$10.50
1週間の範囲:
$9.36
$10.76
52週間の値動き範囲:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
9.40 | 649.81M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.01 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.11 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
780.97 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.69 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.89 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterFootwear buying guidance for consistent weekly training mileage focuses on stable support and balance, making it a solid option for daily use. - ulpravda.ru
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Market Sentiment & Verified Entry Point Signals - ulpravda.ru
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Can Fulcrum Therapeutics Inc. stock surprise with earnings upside2025 Volume Leaders & Stock Timing and Entry Methods - ulpravda.ru
Will Fulcrum Therapeutics Inc. stock outperform Dow Jones indexWeekly Profit Report & Long-Term Capital Growth Strategies - ulpravda.ru
How geopolitical tensions affect Fulcrum Therapeutics Inc. stock2025 Biggest Moves & Pattern Based Trade Signal System - ulpravda.ru
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionPrice Action & Community Trade Idea Sharing Platform - ulpravda.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: A Biotech With A 90% Upside Potential - DirectorsTalk Interviews
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Currency Fluctuation Impact & Consistent Triple Returns - ulpravda.ru
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
2026 world cup results breakdown: Is Fulcrum Therapeutics Inc. stock supported by strong cash flows2026 world cup usa national team round of 32 playmakers pressing system odds analysis expert opinion - ulpravda.ru
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3%Time to Sell? - MarketBeat
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 3%Should You Buy? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fulcrum Therapeutics Earnings Notes - Trefis
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7%Should You Sell? - MarketBeat
RBC Capital maintains Fulcrum Therapeutics (FULC) sector perform recommendation - MSN
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study - Insider Monkey
Fulcrum Therapeutics (FULC) Price Target Increased by 32.56% to 19.38 - Nasdaq
Retail Trends: Why Fulcrum Therapeutics Inc stock is a must watch in 20252025 Investor Takeaways & High Yield Stock Recommendations - moha.gov.vn
FULC (Fulcrum Therapeutics) Price-to-Tangible-Book : 3.35 (As of Dec. 20, 2025) - GuruFocus
What makes Fulcrum Therapeutics Inc. stock attractive to growth fundsJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Why Fulcrum Therapeutics Inc. stock is considered a top pick2025 Retail Activity & Free Technical Pattern Based Buy Signals - Улправда
Is Fulcrum Therapeutics Inc. stock undervalued vs historical averages2025 Performance Recap & Community Driven Trade Alerts - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc. stock is a must watch in 2025 - Улправда
Published on: 2025-12-19 18:03:13 - DonanımHaber
Can Fulcrum Therapeutics Inc. stock deliver consistent earnings growthQuarterly Performance Summary & High Win Rate Trade Tips - DonanımHaber
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Market Trends: Will Fulcrum Therapeutics Inc. stock attract more institutional investorsWeekly Investment Report & Technical Entry and Exit Tips - Улправда
Insider Sell: Curtis Oltmans Sells Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
B of A Securities maintains Fulcrum Therapeutics (FULC) underperform recommendation - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% on Insider Selling - Defense World
Truist Financial Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - ca.investing.com
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com India
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.27%
大文字化:
|
ボリューム (24 時間):